Tucatinib tablets 150mg/tablet, 60 tablets/box

Medication Safety Tips

Use this product according to its instructions, medical advice, and your health needs. Shipping is arranged after payment once the order meets dispatch requirements.

Contraindications

Warnings and Precautions
• Diarrhoea: Severe diarrhoea including dehydration, acute kidney injury and death has been reported. Antidiarrheal therapy as clinically indicated. Depending on the severity, the dose is interrupted and then reduced, or LuciTuca is permanently discontinued.
• Hepatotoxicity: Serious hepatotoxicity has been reported with LuciTuca. ALT, AST, and bilirubin are monitored prior to initiation of LuciTuca, every 3 weeks during treatment, and as clinically indicated. Depending on the severity, the dose is interrupted and then reduced, or LuciTuca is permanently discontinued.
• Embryo-fetal toxicity: TLuciTuca can cause fetal harm. Inform the patient of the potential risks to the fetus and use effective contraception.
In addition, please refer to the full prescribing information for trastuzumab and capecitabine for pregnancy and contraception information.

Medication risks

Adverse Reactions
• The most common adverse effects (≥ 20%) of LuciTuca in combination with trastuzumab and capecitabine in patients with metastatic breast cancer are diarrhea, hand-foot swelling, nausea, hepatotoxicity, vomiting, stomatitis, loss of appetite, anemia, and rash.
• The most common adverse effects (≥ 20%) of LuciTuca in combination with trastuzumab in patients with unresectable or metastatic colorectal cancer are diarrhea, fatigue, rash, nausea, abdominal pain, transfusion-related reactions, and pyrexia.